Understanding how the Epstein-Barr virus affects B cells in cancer
B cell determinants of EBV latency
This study is looking at how the Epstein-Barr virus might cause certain types of blood cancers in people with HIV, and it aims to find out how the virus behaves in the body so that new treatments can be developed for those affected.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10894907 on NIH RePORTER |
What this research studies
This research investigates the role of the Epstein-Barr virus (EBV) in causing various types of B-cell lymphomas, particularly in patients with HIV. By using advanced techniques like CRISPR and chemical genetics, the study aims to identify the host factors that regulate EBV's behavior in B cells. The goal is to uncover the mechanisms that allow EBV to persist in the body and contribute to cancer development, which could lead to new treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with HIV who are at risk for EBV-associated lymphomas.
Not a fit: Patients without HIV or those not affected by EBV-related cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that target EBV-related cancers, improving outcomes for patients.
How similar studies have performed: Previous research has shown promising results in understanding viral latency and its implications for cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Cesarman, Ethel — Weill Medical Coll of Cornell Univ
- Study coordinator: Cesarman, Ethel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.